Home > Search Clinical Trials > Healthy Volunteer
Clinical Trials: Healthy Volunteer
IRB No. 01-262-1 (Dr. Marion Frank, PI): Human Salty and Bitter Taste Mechanisms
Study description not available
IRB No. 13-033S-2 (Dr. Martin Cherniack, PI): Health Improvement through Training and Employee Control 2
Study description not available
IRB No. 19-205-2 (Dr. Jenna Bartley, PI): Vaccination Efficacy with Metformin in Older Adults: A Pilot Study (VEME)
VEME is a double-blinded placebo-controlled trial in men and women over the age of 65 years. It will determine whether metformin can increase influenza (flu) vaccine efficacy in older adults, specifically focusing on cell-mediated responses. Participants will be randomly assigned to either metformin or placebo treatment for a total of 22 weeks. Participants will be vaccinated with high-dose flu vaccine after 12 weeks of treatment. Blood will be drawn prior to treatment, prior to vaccination (week -12 and week -5), and 1, 5, and 10 weeks post vaccination. Peripheral blood mononuclear cells (PBMCs) will be analyzed for cell-mediated responses and serum will be used for flu antibody titers. The overall hypothesis is that metformin will enhance flu vaccine efficacy via targeting age-related changes in intracellular metabolism of immune cells. Primary Outcome: The primary outcome is cell-mediated immune responses to flu vaccine, specifically inducible Granzyme B (GrB) and interferon-? (IFN-?)/interleukin-10(IL-10) ratio in PBMCs stimulated with live flu virus. Secondary Outcomes: Secondary outcomes include flu antibody titers, frailty phenotype, and T cell metabolic cellular profiles. Population: Forty older adults (65 years and older), with approximately 50% men and 50% women. VEME will exclude persons with prediabetes, diabetes, and contraindications to receiving metformin or the flu vaccine. Study Agent: Metformin Hydrochloride Extended-Release, 1500mg/day (three 500mg ER tablets once a day, starting at 500mg ER/day and progressed per current recommendations) and high dose quadrivalent inactivated influenza vaccine (Sanofi Pasteur Inc) Participant Duration: 22 weeks of treatment (up to 27 weeks of participation from screening visit) Study Duration: Recruitment and screening will take place approximately May to July. First dosing of first patient will begin approximately July 15th at the earliest and the first dosing of the last patient will be approximately September 4th at the latest (flu vaccination after 12 weeks of treatment, between October and November). The last patient last visit will be approximately February 10th at the latest (10 weeks post flu vaccine with + 1 week flexibility range).
IRB No. 19-121JS-1 (Dr. Daniel Rosenberg, PI): Ellagic acid, urolithins and colonic microbial communities affected by walnut consumption
The purpose of this study is to investigate whether adding walnuts to your diet can have a beneficial effect on your colon. Walnuts contain a natural compound called ellagitannin that is broken down in the stomach to ellagic acid. Ellagic acid is further broken down by your gut microbiota into a group of polyphenolic compounds called urolithins that have powerful anti-inflammatory actions. The gut microbiota is defined as the community of bacteria, fungi, viruses, etc. that live in your gut. Increasing evidence suggests that polyphenol consumption is associated with lower risk of colorectal cancer. We aim to investigate how a person's gut microbiome may contribute to your ability to form these powerful antioxidant urolithin compounds. Antioxidants are a group of substances that have the ability to reduce inflammation. In this study, we will collect demographic information and dietary records, and perform tests on proteins, DNA and/or RNA from samples of colon biopsies, blood, stool and urine to investigate how a person's microbiome may contribute to their ability to form urolithins.